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Abstract
Background: Nearly fifteen years after the start of WHO’s DOTS strategy, tuberculosis remains a major global health
problem. Given the lack of empirical evidence that DOTS reduces tuberculosis burden, considerable debate has arisen about
its place in the future of global tuberculosis control efforts. An independent evaluation of DOTS, one of the most widely-
implemented and longest-running interventions in global health, is a prerequisite for meaningful improvements to
tuberculosis control efforts, including WHO’s new Stop TB Strategy. We investigate the impact of the expansion of the DOTS
strategy on tuberculosis case finding and treatment success, using only empirical data.
Methods and Findings:We study the effect of DOTS using time-series cross-sectional methods. We first estimate the impact
of DOTS expansion on case detection, using reported case notification data and controlling for other determinants of
change in notifications, including HIV prevalence, GDP, and country-specific effects. We then estimate the effect of DOTS
expansion on treatment success. DOTS programme variables had no statistically significant impact on case detection in a
wide range of models and specifications. DOTS population coverage had a significant effect on overall treatment success
rates, such that countries with full DOTS coverage benefit from at least an 18% increase in treatment success (95% CI: 5–
31%).
Conclusions: The DOTS technical package improved overall treatment success. By contrast, DOTS expansion had no effect
on case detection. This finding is less optimistic than previous analyses. Better epidemiological and programme data would
facilitate future monitoring and evaluation efforts.
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Introduction
After two decades of neglect by the international community,
tuberculosis was again recognised as a major global health
problem in the late 1980s.[1] The most recent global burden of
disease figures[2] show that tuberculosis makes up 2.6 percent of
burden in middle- and low-income countries, making it the ninth
leading cause of death and disability worldwide; this estimate does
not include tuberculosis in the context of HIV infection. The
World Health Organization (WHO) estimates that 1.6 million
people died of tuberculosis in 2005, of whom 190 000 were HIV-
positive.[3] In part because of the powerful interaction between
HIV and tuberculosis, global tuberculosis incidence is estimated to
be rising.[4] Surveillance data suggest that multi-drug resistance
(MDR) is significant in several countries with the highest burden of
tuberculosis,[5] and recent reports of highly lethal strains of
extensively drug-resistant tuberculosis[6] highlight the potential
threat of expanding resistance.
WHO’s tuberculosis control strategy has its roots in the now
classic demonstration by Styblo in the 1980s that high treatment
success rates were achievable in low-income settings from sub-
Saharan Africa to Latin America.[7] Styblo’s approach was
adopted by the World Health Assembly in 1991 and renamed the
DOTS (Directly Observed Therapy, Short-course) Strategy in
1994. The DOTS strategy has four key technical pillars: detection
of smear-positive pulmonary tuberculosis using sputum microsco-
py, in patients presenting themselves to public clinics; directly-
observed treatment with short-course chemotherapy; guaranteed
continuous drug supply; and a case recording system tracking
treatment outcomes. Early 2006 saw the launch of WHO’s
updated Stop TB strategy, designed to address three major
challenges in tuberculosis control: continuing DOTS expansion,
dealing with emerging types of tuberculosis like HIV-TB and
MDR-TB, and engaging the broader health system including the
private sector[8]; however, the four technical pillars of DOTS
remain the ‘‘cornerstone’’ of the revised approach.[3]
The DOTS strategy has been adopted by 187 of 193 WHO
member states at high levels of population coverage: WHO
estimates that 89 percent of the world’s population were living in
areas implementing DOTS by the end of 2005.[3] While such
administrative data do not necessarily reflect the proportion of all
tuberculosis cases detected or the realities of patient access to care
in developing countries, DOTS remains at the policy level one of
the most widely-implemented and longest-running global health
PLoS ONE | www.plosone.org 1 March 2008 | Volume 3 | Issue 3 | e1721
interventions in history. Given that DOTS will likely continue to
occupy a central place in global tuberculosis control efforts in
coming years, the question of what DOTS has or has not
accomplished over the past 15 years is a central technical question;
it is also critical to global health transparency and accountability.
WHO has evaluated the performance of DOTS in the course of
specific studies[9–11] as well as detailed annual reports since
1997.[3,12–21] These publications make use of two major
indicators of programme performance: treatment results among
patient cohorts and percent of incident tuberculosis cases detected
by national programmes. The former indicator is based on real
data collected in countries. The latter is difficult to study
empirically given the paucity of data on the incidence of clinical
tuberculosis, which forms the denominator of the case detection
rate. A recent review concluded that only 10 sputum prevalence
surveys exist as inputs to WHO’s estimates of incidence for 211
countries and territories; of these only 4 were deemed rigorous,
representative, and recent enough to provide useful informa-
tion,[22] though a recent study[23] meeting the review criteria
would bring the total to five. In a further 64 high-income countries
with high-quality vital registration and surveillance systems,[24] it
may be possible to assume that case notifications approximate
incidence,[25] leaving 142 countries and territories without any
credible information. WHO’s estimation strategy for the these
areas, which has been described in detail elsewhere,[26] is to
directly guess the case detection rate on the basis of expert opinion.
This number is then translated into an estimated incidence rate by
taking advantage of the definition of the case detection rate: case
notification rate over incidence rate. This circular strategy, in
which guesses about programme performance feed into metrics
used to evaluate programme performance, makes rigorous
monitoring and evaluation difficult.
Given the difficulties of evaluating DOTS globally based on
non-empirical estimates of its performance or flawed data, a
limited number of studies have examined performance at country
level.[27–30] These have shown mixed results, and those showing
positive impact are weakened by methodological problems. First,
they do not control for known determinants of tuberculosis
incidence, notably HIV infection and socioeconomic develop-
ment. Second, some studies make the questionable assumption
that case notifications are an unbiased measure of incidence.
Third, they do not differentiate the impact of increased financing
from the technical elements of DOTS. Given the lack of firm
evidence on the effectiveness of DOTS, many commentators have
started to question some of the most fundamental principles of the
strategy, most notably its effectiveness in case detection; its
applicability in high-HIV, MDR, and resource-poor settings; and
the validity of direct observation.[9,31–43]
In this paper, we investigate the impact of the adoption of the
DOTS strategy on case detection and treatment, the two goals of
tuberculosis control programs. Like previous studies, our starting
point is data on case notifications and reported outcomes of case
treatment. Our approach differs from other efforts, however, in
four ways. First, we restrict our analysis to data measured in
countries, rather than a priori expert opinions with limited
empirical inputs. Second, we use accepted methods of statistical
inference to test the impact of DOTS expansion. Third, we
identify and address known biases and distortions in the empirical
record. Fourth, our evaluation is independent, in that none of the
authors of this study has a professional or financial stake in the
success of the DOTS strategy. This avoids the conflict of interest
that can arise when organizations assess their own performance.
We build on previous studies of the effectiveness of global health
interventions using similar methods.[44,45] This evaluation may
have significant implications for the future of the Stop TB strategy,
allowing policy planners to correctly identify priority areas for
strategic and operational improvement in light of the accomplish-
ments of the past 15 years. It may also inform thinking on a range
of emerging health interventions that require case detection and
delivery of life-long treatment, from medications for diabetes and
cardiovascular disease[46] to antiretrovirals for AIDS.[47]
Methods
We seek to analyse the impact of the DOTS strategy on two key
dimensions of tuberculosis control: case detection rate (CDR),
defined as the ratio of notified to incident cases, and treatment
success rate (TSR), defined as the sum of the fraction of cases
completing treatment and the fraction converting from smear-
positive to negative. Direct assessment of the impact of DOTS on
case detection would require data on tuberculosis incidence, which
is unknown. Our analytic method takes advantage of the
relationship between case notification rate (the ratio of notified
cases to population), and case detection rate: changes in
notifications are driven by changes in detection or changes in
incidence. Our model (described in more detail in Technical
Appendix S1) analyzes notifications as a function of epidemiolog-
ical correlates of tuberculosis as well as programmatic variables.
This analytically isolates determinants of incidence from other
drivers of change in notifications, so that any remaining change in
notification rate becomes attributable to change in case detection.
Since the definition of a smear-positive case is largely consistent
across time and place, and since smear-positive cases have been
the primary target of the DOTS strategy since its inception,[3] we
focus our analysis on smear-positive notification rate (SSNR).
In general, only omitted determinants of case notifications that
are correlated with changes in programmes would introduce bias,
while determinants uncorrelated with programme changes would
not. For example, changes in the way cases are reported to WHO
can also produce changes in the case notification rate. If these
changes are non-random, for example if DOTS expansion
improves tuberculosis reporting systems without affecting true
detection rate, our results could be biased in favour of detecting a
programme effect. We thus perform a literature review to identify
countries with evidence of changes in reporting modality for
tuberculosis cases, for example changes in case definitions or
introduction of electronic or Internet-based technologies, over the
time period of our analysis.
In order to capture determinants of variation in incidence, we
include two main variables. First, we include country-level
estimates of HIV population seroprevalence,[48] constructed by
UNAIDS on the basis of empirical data from surveillance sites and
population-based surveys;[49] this restricts our analysis to 121
developing countries for which both HIV estimates and DOTS
programme data are available, including 21 of 22 ‘‘high-burden’’
countries.[3] HIV prevalence is lagged by five years to account for
the period during which significant immune compromise acceler-
ates breakdown from latent tuberculosis infection to clinical
disease. Second, GDP per head is included to control for the well-
known relationship between tuberculosis incidence and socio-
economic status.[50,51] We also test other variables that may
contribute to or correlate with changes in tuberculosis incidence:
smoking impact ratio,[52] apparent cigarette consumption,[53]
population age structure, urbanization, total years of schooling,
and literacy rates.[54] Finally, we also test factors unrelated to
DOTS expansion that may contribute to increased case detection:
national health expenditure per head, and estimated coverage
levels of diphtheria, tetanus, and pertussis vaccination (DTP3).[55]
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Including the latter is based on the assumption that coverage of a
basic health intervention measures general health system coverage,
with the goal of isolating the impact of DOTS from that of health
system change.
Our major indicator of DOTS expansion is DOTS population
coverage (DPC), defined and reported by WHO as the percentage
of national population living in areas (e.g., districts, counties)
implementing DOTS. Population coverage is used by WHO as
the primary measure of DOTS expansion, along with estimated
case detection rate. To further confirm the validity of this measure,
we explore the relationship between population coverage and
percent of all cases notified under DOTS in countries, and find a
significant positive relationship (univariate OLS: R2=0.78,
b=0.88, p,0.0001). We use this indicator as a measure of DOTS
expansion at the administrative level. We also use DOTS
treatment success rate as an independent variable, based on the
assumption that higher success rates indicate higher programme
quality on the ground. Because population coverage and treatment
success both measure programme delivery, we test one variable at
a time rather than both in the same model.
We next seek to analyse the impact of DOTS expansion on
overall treatment success rate; this is only available for smear-
positives. Countries report treatment outcomes separately for
DOTS and non-DOTS cohorts, but the dataset contains many
missing values (41 percent of all country-years from 1995 to 2005
for DOTS, 79 for non-DOTS). To test the impact of adoption of
the DOTS strategy on overall treatment success, we restrict the
analysis to country-years where treatment success is reported for
both DOTS and non-DOTS cases. We calculate mean treatment
success rate (DOTS and non-DOTS, weighted by number of
cases) and model it as a function of DOTS population coverage,
controlling for general development by using GDP per head. We
perform the analysis both with and without HIV seroprevalence,
to control for the possibility of poorer outcomes in HIV-positive
patients.[56–58]
We construct all models using standard time-series cross-
sectional methods[59,60] with a lagged dependent variable[61]
and country fixed effects (i.e., dummy variables)[62] to capture the
effect of omitted variables and isolate changes produced by DOTS
programme variables. Fixed effects are used to capture differences
in incidence, case detection, and determinants of treatment success
that are specific to individual countries and invariant over the
period of observation; in other words, they are by definition
unrelated to the rollout of the global DOTS strategy. Since our
dataset contains multiple observations from the same country over
time, there is the risk of non-independence in standard errors; we
correct for this by clustering standard errors by country.[63]
Technical Appendix S1 contains more details regarding our data
sources and methods, as well as supplemental models not
presented in the main text.
Results
Figure 1 shows the total number of tuberculosis cases of all
forms reported to WHO since 1980. Any changes in the number
of cases reported may be due to changes in six factors: 1) case
detection rate, 2) incidence rate, 3) population size, 4) case
definitions, 5) proportion of detected cases that are recorded at the
local level, and 6) proportion of cases recorded in the periphery
that are reported to the central government and to WHO. Our
analysis seeks to minimise confounding referable to factors other
than changes in incidence and case detection rate. Since the latter
four factors are either measurable or to some extent predictable,
they are addressed in the analysis. The effect of population growth,
for example, can be removed by using case notification rate
(CNR): dividing notifications by population, we calculate that
global case notification rate varied between 57 and 71 per 100 000
population from 1980 to 2003; they surpassed 70 per 100,000 in
1990 and again in 2004, then increased to 79 per 100 000 in 2005.
Evolving definitions of smear-positive cases are likely responsible
for the fluctuation in case numbers seen in the early 1990s; we thus
restrict our analyses to the period from 1995–2005, when
consistent data are available.
Improvements in recording and reporting technology are more
difficult, but equally necessary, to consider. Results of a literature
review indicate that at least ten countries transitioned fully or
partially to electronic reporting systems over the period of our
Figure 1. Total smear-positive and smear-negative tuberculosis cases notified to WHO, 1980–2005
doi:10.1371/journal.pone.0001721.g001
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analysis: Botswana, China, India, Indonesia, Korea, Lesotho,
Namibia, Nepal, Philippines, and South Africa.[3,20,21,64–69]
Such changes can distort case notification trends by increasing the
number of cases reported to the centre without affecting case
detection on the ground, complicating interpretation of time
trends. Figure 2 shows trends in notified cases for six of these
countries, illustrating discontinuities in number and composition of
reported cases. Since these may be referable to arbitrary changes
in reporting modality rather than sudden changes in incidence or
detection, we undertake all subsequent analyses both with and
without these ten countries.
Figure 3 presents the trend in the number of smear-positive
cases notified to WHO from 1995 to 2005 alongside changes in
DOTS population coverage, with and without countries that
Figure 2. Tuberculosis cases reported to WHO in six of ten countries with known recent transitions to electronic case recording or
reporting, 1980–2005
doi:10.1371/journal.pone.0001721.g002
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adopted electronic reporting over the period of analysis. When
these countries are removed, the sharp upturn since 2003
disappears and smear-positive notifications increase steadily from
20 per 100 000 in 1995 to 29 per 100 000 in 2005, 43 percent in
ten years. The composition of the total smear-positive cases
detected has shifted dramatically from non-DOTS to DOTS.
The four models in Table 1 attempt to characterise the relative
contribution of changes in tuberculosis incidence and changes in
case detection rate, including the impact of DOTS programmes,
on smear-positive notifications. In all models, the one-year lagged
smear-positive notification rate is significant, confirming the
presence of serial autocorrelation (Wooldridge test, p,0.0001).
GDP per head has no significant effect on notifications, and HIV
seroprevalence is significant only in models with treatment success
as the programme variable. Neither DOTS population coverage
nor treatment success rate has a statistically significant relationship
on the case notification rate in these models, or a wide range of
alternative specifications and analyses. Repeating our analysis on
notification rates for all forms of tuberculosis likewise shows no
DOTS effect. Increasing urbanization significantly raises notifica-
tion rates, but including this variable has no impact on the DOTS
coefficients. Technical Appendix S1 Tables S1, S2, S3 contain
results from additional models.
The magnitude of total change in overall treatment success rate
as a result of DOTS expansion is unknown, since reporting on
treatment outcomes in non-DOTS programmes is scattered and
often inconsistent. In order to rigorously assess the impact of
DOTS on the treatment success rate, we examine countries that
report in the same year treatment success data for both DOTS and
non-DOTS smear-positive cases. The available data on DOTS
and non-DOTS treatment success in these countries are
summarised in Figure 4. The difference in the median treatment
success rate over this period ranged from 5 to 14%.
While DOTS treatment success rate is consistently higher, this
could reflect a correlation rather than a direct effect of DOTS
expansion on mean country treatment success. Because of serial
autocorrelation (Wooldridge test, p,0?0001) we use methods
requiring data on the concurrent and prior-year success rates,
which restricts our analysis to under 200 country-years. Table 2
summarises the results for two models, with and without HIV.
GDP per head and HIV seroprevalence are non-significant.
DOTS population coverage is statistically significant in both
Figure 3. Smear-positive tuberculosis notifications, shown alongside DOTS coverage, 1995–2005; Figure 3a (top): Smear-positive
tuberculosis notifications to WHO, as reported vs excluding countries with known transitions to electronic tuberculosis reporting
(ETBR: Botswana, China, India, Indonesia, Korea, Lesotho, Namibia, Nepal, Philippines, South Africa), 1995–2005; Figure 3b
(bottom): Percent of world population living in areas (e.g., districts, counties) implementing DOTS, 1995–2005
doi:10.1371/journal.pone.0001721.g003
Has DOTS Worked for TB Control
PLoS ONE | www.plosone.org 5 March 2008 | Volume 3 | Issue 3 | e1721
models for this limited dataset. The DPC coefficient in the model
including HIV indicates that expanding DOTS coverage from
zero to 100 percent of the population raises mean treatment
success rate by 18 percent (95% confidence interval: 5–31%).
Given the small sample size and the fact that the coefficient on the
lagged success rate was non-significant, we also repeat the analysis
without the lagged variable; this increases sample size by
approximately 70 country-years, but does not alter the results
(see Technical Appendix S1 Table S4).
Discussion
Despite the realities of limited data on tuberculosis, our analysis
provides empirical evidence that the expansion of the DOTS
strategy led to improved treatment success rates. This finding is
significant in the setting of debate as to the actual impact of direct
observation on treatment success, particularly health facility-based
direct observation in countries with sparse health infrastruc-
ture.[40,70–73] This analysis, however, cannot identify which
Table 1. Smear-positive notification rate as a function of GDP, HIV, and DOTS programme variables, 1995–2005
All countries Excluding countries with electronic reporting
Model 1 Model 2 Model 1 Model 2
GDP per head, Coefficient 0.008 0.006 0.005 20.004
USD thousands SE 0.008 0.013 0.008 0.010
HIV seroprevalence Coefficient 0.45 1.40 0.40 2.63
(five-year lag) SE 0.52 0.53 1.01 1.11
DOTS population coverage fraction Coefficient 0.05 - 0.04 -
SE 0.05 0.05
DOTS treatment success fraction Coefficient - 0.04 - 0.02
SE 0.12 0.13
Lag of SSNR Coefficient 0.56 0.49 0.55 0.47
(one year) SE 0.05 0.05 0.05 0.04
Constant Coefficient 0.69 1.14 0.82 1.23
SE 0.27 0.14 0.28 0.35
Observations (country-years) 1128 887 1024 792
R2 0.95 0.96 0.95 0.95
Coefficients significant at the 0.05 level are in bold. All standard errors are clustered by country.
*Excluded: Botswana, China, India, Indonesia, Korea, Lesotho, Namibia, Nepal, Philippines, S Africa
(Independent programme variable: Model 1—DOTS population coverage, Model 2—DOTS treatment success rate)
doi:10.1371/journal.pone.0001721.t001
Figure 4. Median and 10–90th percentile range of treatment success rates for countries reporting DOTS and non-DOTS treatment
outcomes, 1995–2004
doi:10.1371/journal.pone.0001721.g004
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element of the overall DOTS technical package has been effective
in increasing treatment success rate. Given the literature on
treatment outcomes in HIV-positive tuberculosis patients, we feel
that the model incorporating HIV is the most credible, implying
an increase of 18 percent with full DOTS coverage. This number
may well be biased downward, due to the small sample of
countries and to the possibility of selection effects: countries that
consistently report non-DOTS treatment outcomes are likely to
have better non-DOTS programmes than countries that do not.
Given this potential bias, the results should be interpreted as the
minimum effect of the DOTS strategy on treatment success rates.
In contrast, the analysis failed to detect any impact of national
adoption of the DOTS strategy on case notifications, and by
inference case detection rates, when controlling for determinants of
tuberculosis incidence. This conclusion was robust across a wide
range of specifications and functional forms. This finding is
considerably less optimistic than recent reports, which imply that
DOTS expansion has driven increases in estimated smear-positive
case detection rate from approximately 40 percent in 1995 to 2000
to 60 percent in 2005—a 50 percent increase in five years.[3] As
noted above, our technical approach differs from previous efforts in
three ways: use of accepted statistical methods, correction for known
biases, and use of empirical data. Given the discordance of our
finding with previous studies, it is important to discuss the potential
reasons that our time-series cross-sectional analysis may be flawed.
First, it is possible that these methods are not sufficiently sensitive
to detect the impact of DOTS expansion on case notifications. Panel
regression techniques, however, are widely used and accepted in the
econometric and political science literature, and have been used to
measure effects in a wide variety of fields from political economy to
international relations.[74] In addition, the fact that these methods
detect the effect of DOTS expansion on treatment success rate in all
models argues against this interpretation.
Second, if we have omitted factors predicting declines in case
notifications that are also correlated with DOTS coverage, our
estimate of the impact of DOTS on case detection would be biased
downward. One possibility would be that DOTS population
coverage itself has an immediate negative effect on incidence,
which exactly balances a positive DOTS effect on case detection
rate. However, this possibility seems unlikely given the natural lags
built into the epidemiology of tuberculosis: changes in risk of
infection affect incidence of active cases only after a significant
period of breakdown from latent infection to clinical disease,
generally much longer than the one-year units of this analy-
sis.[75,76] We have been unable to identify other drivers of
notifications that would be negatively correlated with DOTS
population expansion. Indeed, unlike previous evaluations of
DOTS, we explicitly control for several sources of bias in case
detection trends. Variables measuring HIV seroprevalence,
income per head, and time-invariant attributes of countries (i.e.,
fixed effects) are included to isolate the effect of DOTS more
precisely, and none would be expected to obscure the presence of a
true effect. GDP was found to be non-significant in nearly all
models, and HIV was only significant in some models; this may
reflect the fact that GDP or HIV growth within countries over the
study interval is small relative to the across-country differences,
meaning that country dummy variables capture most of the effect.
In the case of HIV, this may also indicate that case notifications
are not growing at a rate commensurate with increasing TB-HIV.
Third, any analysis based on case notification data may be
biased towards detecting a positive DOTS effect, as institution of
DOTS may lead to improved reporting of cases already detected.
Spurious trends due to reporting changes are ubiquitous in the
case notification series. The massive increase in cases reported in
China from 2003 to 2005 coincides with the introduction, in the
wake of the SARS epidemic, of a mandatory Internet-based case
reporting system for all infectious diseases, covering nearly all
county hospitals and tuberculosis clinics, and a large fraction of
village dispensaries.[21,65] Since the start of DOTS implemen-
tation in China under the auspices of the World Bank, there has
been widespread recognition that cases of tuberculosis diagnosed
in general hospitals were under-reported: hospitals have a
powerful financial incentive not to report cases to the tuberculosis
programme, in order to maintain revenues from patients. The new
surveillance laws and reporting system now make it difficult for
hospitals not to report these cases. As a result, a certain number of
cases, which would previously have been diagnosed and treated in
hospitals but not reported to tuberculosis clinics, began to be
centrally reported. There is no reason to believe that this
represents a real increase in the number of cases detected.
Similarly, the major increase in cases from 2002 to 2005 in South
Africa coincides with the roll-out of an electronic case notification
system[66,77] in the country’s largest provinces, which again
reflects better recording of cases centrally rather than a true rise in
the number of cases diagnosed. Clearly, reporting changes
introduce distortions into case notification trends, and we chose
to perform our analyses both with and without countries with
known changes to minimize arbitrary changes in the series. While
these countries account for a large percent of all tuberculosis cases
(53 percent between 2001 and 2005), they represent only a small
minority of the 121 national DOTS programmes that are the unit
of this analysis. In any case, exclusion of these countries had no
appreciable impact on results. Since WHO does not systematically
report on changes in reporting modalities, it is impossible to
exclude the possibility that reporting changes in other countries
may be affecting our results; however, this would result in upward
bias, not downward bias, and thus would not explain our finding
that DOTS has no effect on case detection.
The analytical approach of this paper, using case notifications to
detect the impact of DOTS on case detection by controlling for
Table 2. Mean national treatment success rate (DOTS and
non-DOTS, weighted by cases) as a function of GDP, HIV, and
DOTS population coverage, all countries, 1996–2004
Without HIV With HIV
GDP per head, Coefficient 0.002 0.006
USD thousands SE 0.009 0.014
HIV seroprevalence Coefficient - 20.28
SE 0.35
DOTS population coverage
fraction
Coefficient 0.16 0.18
SE 0.05 0.07
Lag of TSR Coefficient 0.21 0.21
(one year) SE 0.21 0.21
Constant Coefficient 0.31 0.64
SE 0.19 0.18
Observations (country-years)* 191 159
R2 0.81 0.81
Coefficients significant at the 0.05 level are in bold. Standard errors are
clustered by country.
*Model with HIV includes 45 countries, models without HIV include 55
countries; both include countries from all six WHO regions.
doi:10.1371/journal.pone.0001721.t002
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determinants of incidence, would not be necessary if real measures
of tuberculosis epidemiology were available. The approach of
WHO to date has been to strengthen routine tuberculosis
surveillance systems in the developing world, such that as coverage
approaches 100 percent, case notifications become a reasonable
measure of incidence.[25] Given the failure of most countries to
implement even basic vital registration systems after decades of
effort,[78] it is clear that complete surveillance coverage is an
ambitious goal. Better data on real trends in tuberculosis
epidemiology are needed in the interim.
While there may in fact be an opportunity to track trends in
tuberculosis by examining death rates in those countries with
complete vital registration,[79] direct measures of tuberculosis
incidence or prevalence remain the gold standard for epidemiolog-
ical surveillance. At least eleven countries have undertaken serial
population-based sputum prevalence surveys over the last
60 years,[23,80] but given the substantial costs of this approach,
there is little prospect that such surveys will provide a widespread
basis for the frequent epidemiological measurements required for
monitoring. For some countries, serial skin test surveys are
available.[81] Interpretation of these, however, is legendarily difficult
due to confounding from inconsistent definitions of infection,[82]
environmental mycobacteria,[83,84] ‘boosting’ from repeat test-
ing,[85] BCG vaccination,[86,87] and increasing selection bias in
BCG scar-negative children. To make epidemiological surveys a
viable tool in countries without the resources to implement
prevalence surveys, new measurement strategies are clearly needed.
Pending the development of such methods, case notifications
are a key indicator of programme performance. Thus any efforts
to disentangle changes in reported case numbers—due for
example to the adoption of new reporting technologies in China,
South Africa, and elsewhere—from real trends in the number of
new cases detected would represent a major contribution to
monitoring performance. WHO currently presents increases in
case notifications due to reporting changes as real increases in the
case detection rate, rather than concluding that their previous
estimates were artificially depressed by poor reporting.[21] Indeed,
on the basis of the spurious trend resulting from China’s new
Internet-based reporting system, a major increase in global case
detection has been claimed.[88]
There are three potential ways to explain why DOTS failed to
increase case detection. First, the problem could be one of resource
constraints. Including tuberculosis programme expenditures in the
models would have allowed us to distinguish the impact of DOTS
expansion from changes in funding levels, but comparable
expenditure data are not available globally.[3] Second, current
constraints of developing countries’ health systems, including
inadequate geographical and financial access to facilities or severe
limitations of human resources, may be limiting the effectiveness of
DOTS. The Stop TB strategy’s emphasis on engaging health
systems and the private sector is one potential solution to this
problem. In poor rural areas of developing countries, however,
where there are no private and few public providers, even the Stop
TB strategy may not be sufficient. Finally, it is possible that the
DOTS technical strategy itself limits the potential case detection
rate. Though the DOTS strategy has ambitious targets for
increasing detection, the emphasis on ‘passive’ case finding means
that there is no provision in the key components of the strategy
that specifically pertains to finding new cases. Aspects of the Stop
TB strategy such as Public-Private Mix DOTS[89] aim to
transition non-DOTS patients into DOTS programs, thus
allowing them to benefit from higher DOTS treatment success
rates and free care. This represents a positive development.
However, it is crucial to distinguish between such activities—
improvements in the care of patients already detected—and the
detection of truly new cases. The new Stop TB strategy contains
some provisions for increasing true case detection,[90] but there is
no indication that empirical evaluations of these strategies have
been performed or planned, raising the possibility that they may
not have the desired impact. Screening for tuberculosis in the
context of HIV services, for example, is limited by the fact that
most tuberculosis is estimated to occur in patients without HIV co-
infection.[3] In the absence of clear evidence on the effectiveness
of existing techniques, broadly-applicable new strategies for
actively detecting new cases are urgently needed.
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